Afya's (AFYA) Hold (C) Rating Reaffirmed at Weiss Ratings

Key Points

• Afya's stock has a "hold (c)" rating reaffirmed by Weiss Ratings, while its consensus rating among analysts is "Hold" with an average target price of $18.20.
• Recent ratings updates include upgrades from Wall Street Zen to "strong-buy" and from UBS Group to "buy" with a revised price target of $19.00.
• Afya's shares are currently trading down 1.5% at $14.87, with institutional investors holding over 88.02% of the company's stock.

Afya (NASDAQ:AFYA - Get Free Report)'s stock had its "hold (c)" rating reiterated by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other research firms have also recently weighed in on AFYA. Wall Street Zen upgraded shares of Afya from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 13th. UBS Group raised shares of Afya from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $19.50 to $19.00 in a research note on Monday, September 8th. Zacks Research raised shares of Afya to a "hold" rating in a report on Friday, August 8th. JPMorgan Chase & Co. upgraded shares of Afya from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $23.50 to $24.50 in a research report on Monday, September 8th. Finally, Morgan Stanley set a $17.50 price target on Afya and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $18.20.

Afya Stock Down 1.5%

Shares of AFYA stock traded down $0.23 on Wednesday, hitting $14.87. The company's stock had a trading volume of 44,610 shares, compared to its average volume of 109,412. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.94 and a quick ratio of 0.94. Afya has a fifty-two week low of $13.47 and a fifty-two week high of $19.90. The firm's fifty day moving average price is $15.20 and its 200-day moving average price is $16.82. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 11.27, a P/E/G ratio of 0.47 and a beta of 0.61.

Hedge Funds Weigh In On Afya

Several institutional investors and hedge funds have recently modified their holdings of the stock. Cerity Partners LLC purchased a new position in Afya during the first quarter valued at approximately $476,000. Yorktown Management & Research Co Inc acquired a new stake in shares of Afya during the 1st quarter worth approximately $321,000. Goldman Sachs Group Inc. boosted its holdings in Afya by 167.3% during the first quarter. Goldman Sachs Group Inc. now owns 45,093 shares of the company's stock worth $809,000 after buying an additional 28,226 shares in the last quarter. Doma Perpetual Capital Management LLC boosted its holdings in Afya by 4.4% during the first quarter. Doma Perpetual Capital Management LLC now owns 592,220 shares of the company's stock worth $10,619,000 after buying an additional 25,111 shares in the last quarter. Finally, Perpetual Ltd raised its position in shares of Afya by 1.8% in the second quarter. Perpetual Ltd now owns 151,180 shares of the company's stock worth $2,700,000 after acquiring an additional 2,730 shares during the period. Institutional investors and hedge funds own 88.02% of the company's stock.

About Afya

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.